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Context: The European Thyroid Association (ETA) has classified posttreatment cervical ultrasound
findings in thyroid cancer patients based on their association with disease persistence/recurrence.
Objective: The objective of the study was to assess this classification’s ability to predict the growth
and persistence of such lesions during active posttreatment surveillance of patients with differ-
entiated thyroid cancer (DTC).
Design: This was a retrospective, observational study.
Setting: The study was conducted at a thyroid cancer center in a large Italian teaching hospital.
Patients: Center referrals (2005–2014) were reviewed and patients selected with pathologically-
confirmed DTC; total thyroidectomy, with or without neck dissection and/or radioiodine remnant
ablation; abnormal findings on two or more consecutive posttreatment neck sonograms; and
subsequent follow-up consisting of active surveillance. Baseline ultrasound abnormalities (thyroid
bed masses, lymph nodes) were classified according to the ETA system. Patients were divided into
group S (thosewith one ormore lesions classified as suspicious) and group I (indeterminate lesions
only). We recorded baseline and follow-up clinical data through June 30, 2015.
MainOutcomes: Themain outcomeswere patients with growth (3mm, largest diameter) of one or
more lesions during follow-up and patients with one or more persistent lesions at the final visit.
Results: The cohort included 58 of the 637 DTC cases screened (9%). A total of 113 lesions were
followed up (18 thyroid bed masses, 95 lymph nodes). During surveillance (median 3.7 y), group I
had significantly lower rates than group S of lesion growth (8% vs 36%, P  .01) and persistence
(64% vs 97%, P  .014). The median time to scan normalization was 2.9 years.
Conclusions: The ETA’s evidence-based classification of sonographically detected neck abnormal-
ities can help identify papillary thyroid cancer patients eligible for more relaxed follow-up. (J Clin
Endocrinol Metab 101: 3036–3044, 2016)
Diagnoses of differentiated thyroid cancer (DTC) haveincreased nearly 3-fold since 1975 (1). Most cases
involve papillary thyroid cancers (PTC) with indolent be-
haviors. However, locoregional disease is found in 7%–
28% of PTC patients during follow-up, depending on the
baseline risk class and response to initial therapy (2–5).
ISSN Print 0021-972X ISSN Online 1945-7197
Printed in USA
Copyright © 2016 by the Endocrine Society
Received February 21, 2016. Accepted May 10, 2016.
First Published Online May 17, 2016
Abbreviations: AJCC, American Joint Committee onCancer; ATA, American Thyroid Association;
DTC, differentiated thyroid cancer; ETA, European Thyroid Association; FNAB, fine-needle aspira-
tionbiopsy;PTC,papillarythyroidcancer;RRA,radioiodineremnantablation;Tg, thyroglobulin;US,
ultrasonography.
O R I G I N A L A R T I C L E
3036 press.endocrine.org/journal/jcem J Clin Endocrinol Metab, August 2016, 101(8):3036–3044 doi: 10.1210/jc.2016-1440
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 14 September 2016. at 08:27 For personal use only. No other uses without permission. . All rights reserved.
Almost all of this disease is discovered with cervical ul-
trasonography (US), the most sensitive tool for exploring
the thyroidbedandcervical lymphnode compartments (6)
and the internationally acknowledged cornerstone of the
postoperative surveillance program (5, 7).
Debate continues, however, on the management of
sonographically detected abnormalities, in particular
when these lesions should be subjected to fine-needle as-
piration biopsy (FNAB). Confirmation of locoregional
metastatic involvement often leads to further treatment,
but if this course of action has already been excluded by an
analysis of costs and benefits, FNAB serves little purpose
and can even be an unnecessary source of stress for the
patient. According to the American Thyroid Association
(ATA) practice guidelines, surgery is the preferred treat-
ment for locoregional disease (5), and in expert hands,
neck dissections are acceptably safe procedures. But they
are by no means risk free, particularly when they involve
areas already subjected to surgery (8–10). Moreover, not
all dissections are carried out by experts, and even those
that are can be associated with considerable morbidity.
These considerations become increasingly important in
light of the efficacy rates of these procedures, as low as
40%–50% in some series (11–13), and the fact that in up
to 9% of cases the resected tissues prove to be benign (11,
13, 14). Even when neck lesions are cytologically con-
firmed to be malignant, their progression is usually ex-
tremely slow (15, 16) and their impact on clinical
outcomes far from clear (17–22).
Support is thus growing for the use of more cautious,
conservative strategies for managing sonographically de-
tectedneck lesions inDTCpatients.The2015ATAGuide-
lines allow for active surveillanceof suspicious, nonthreat-
ening lymph nodes whose smallest diameters are less than
8–10 mm. Biopsy should be reserved for lesions that ex-
ceed this limit and/or display active growth, and it should
be used only when management of the case is likely to be
modified if positive findings emerge (5). Specific recom-
mendations are lacking, however, on the management of
small masses detected in the postoperative thyroid bed.
Although some of these lesions are indeed malignant,
many prove to be foci of postoperative fibrosis or suture
granulomas.
In this scenario, the sonographic features of neck le-
sions acquire increasing importance indecisions regarding
the posttreatment management of DTC. Several authors
have described the sonographic characteristics of abnor-
mal lymph nodes and thyroid bed nodules (23–26). Some
features are highly specific in identifying persistence/re-
currence; others are sensitive markers of disease but low
on specificity (23). To aid clinicians in exploiting the di-
agnostic value of these markers, the European Thyroid
Association (ETA) has published a set of criteria for esti-
mating the malignancy risk of sonographically identified
neck masses and lymph nodes based on the assessment of
a series of US characteristics classified as normal, indeter-
minate, and suspicious (27). This study was conducted to
assess the value of this classification in clinical decision
making regarding the use or deferral of FNAB. Our pri-
mary objective was to determine how well this classifica-
tion predicts the evolution of sonographically detected
neck lesions, in terms of persistence and/or growth, during
the posttreatment surveillance of DTC patients. As sec-
ondary end points, we also assessed rates of complications
and the occurrence of new lesions.
Materials and Methods
Study design
We conducted a retrospective observational study in the thy-
roid cancer follow-up center of a large teaching hospital in Italy.
The study protocol was approved by the institutional review
board.Written informed consent was obtained from all patients
whose data were analyzed.
The center’s DTC follow-up protocol
Patients with DTC are initially seen 6–12 months after pri-
mary treatment and at least once a year thereafter. Each visit
includes serum thyroglobulin (Tg) assays (DYNO test Tg-plus,
Brahms Diagnostics GmbH; functional sensitivity 0.2 ng/mL),
radioimmunometric assays of circulating Tg antibodies (Archi-
tect System Anti-Tg; Abbott Laboratories; functional sensitivity
0.31 IU/mL), and high-resolution gray-scale and color Doppler
US of the thyroid bed and cervical lymph node compartments.
The US examinations are performed by an endocrinologist with
specific training and expertise in sonographic examination of the
neck. The characteristics of the examiner and the standard ex-
amination protocol are both in conformity with ETA recom-
mendations (27). Additional imaging studies and/or FNAB for
cytology are ordered at the examiner’s discretion in accordance
with evidence-based guidelines (5, 28).
Study cohort selection and division into subgroups
Wereviewed the center’s casedatabase and identifiedpatients
diagnosedwithDTCandreferred for follow-upbetween January
1, 2005, and December 31, 2014. Those who met the following
criteria were included in the study cohort: 1) surgical pathology
report confirming diagnosis of DTC (ie, papillary, follicular, or
poorly differentiated thyroid cancer); 2) primary treatment con-
sisting of total or near-total thyroidectomy, with or without
central and/or lateral neck dissection and radioiodine remnant
ablation (RRA); 3) abnormal findingsonat least twoconsecutive
neck sonograms performed in our center; and 4) subsequent fol-
low-up consisting solely of active surveillance.
Static images from the baseline US examination (ie, the first
showing abnormalities) were reexamined by an independent re-
viewer. Each thyroid bed or lymph node lesionwas recorded and
classified in accordance with the schema shown in Table 1. The
lesion features considered were those that were routinely eval-
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uated by our staff during the study period. Each was retrospec-
tively designated suspicious or indeterminate in accordancewith
the ETA guidelines (27). When the reviewer’s and original ex-
aminer’s judgmentswerediscordant, bothoperators reexamined
the images and reached a consensus judgment.
The cohort itself was then divided into two groups: group S
comprising patients with at least one lesion classified as suspi-
cious and group I comprising those whose lesions were all con-
sidered indeterminate. Medical records were reviewed and de-
mographic and clinical characteristics recorded for each patient
at the time of thyroid cancer diagnosis, at study baseline, and at
all subsequent visits through June 30, 2015 (data lock).
Analysis of follow-up data
Clinical findings, US images and reports, and laboratory data
relative to each postbaseline follow-up visit were reviewed. We
recorded the results of serum Tg, Tg antibodies, and TSH assays
as well as the location, dimensions, and sonographic features of
each lesion observed (including those appearing after baseline,
provided they were observed on at least two consecutive scans).
The primary end points were growth of one or more lesions at
any time during follow-up and persistence of one or more neck
lesions at the end of follow-up. Growth was defined as an in-
crease of greater than3mmin the largest diameter relative to that
observed at initial detection. Persistent lesions were those still
visualized sonographically at the final visit (ie, the most recent
visit for patients whowere still undergoing active surveillance at
data lock or the last visit in our center before the patient was
referred for treatment, died or was lost to follow-up). We also
recorded the number of lesions that were detected after baseline
(provided they were seen on at least two consecutive scans) and
the number of patients who had clinical evidence of complica-
tions related to lesion growth (dyspnea, dysphagia, bleeding,
skin ulceration).
Statistical analysis
Differences between categorical variables (expressed as num-
bers and percentages) were evaluated with the 2 test or the
Fischer exact test for small samples; differences between contin-
uous variables (reported as medians and ranges) were assessed
with theMann-Whitney test. Values of P .05 were considered
statistically significant. StatView 5.0.1 software (SAS Institute,
Inc) was used for statistical analyses.
Results
Cohort profile at baseline
Six hundred thirty-seven patients with pathologically
confirmed DTC were referred to our follow-up center
between January 31, 2005, and December 31, 2014
(Supplemental Figure 1). In 117 cases (18%), neck US
performed by our staff had revealed one or more abnor-
malities. In 18 of these cases, subsequent US findings were
unavailable (contact interrupted because the patient was
referred directly for treatment or lost to follow-up shortly
after lesion detection or because the next visit was sched-
uled after data lock). In 41 others, none of the lesions
observed at baseline were seen on the subsequent US scan.
The remaining 58 DTC patients constituted the study co-
hort: they had a total of 94 neck lesions, each visualized on
at least two consecutive scans. In all 58 cases, treatment
and/or FNAB were deferred (based on decisions made
jointly by patients and physicians) and the patients placed
under active surveillance.
Their characteristics are summarized in Table 2. All 58
had PTC. The median age at diagnosis was 46 years, al-
most two-thirdswerewomen, and in 71%of the cases, the
ATA risk level was intermediate or high. All had initially
been treated with total thyroidectomy; 25 (43%) had also
undergone some form of neck dissection (central in 13,
lateral in two, both in 10), and over 80% had had RRA.
Postoperatively, all received levothyroxine at doses that
kept serum TSH levels in the low to normal range. At
baseline (ie, at study entry), 10 of the 58 patients (17%)
had already undergone revision neck dissections andwere
being followed up for second neck recurrences. Nine
(16%) had distant metastases.
At baseline, 33 of the 58 patients (57%) had one or
more suspicious lesions and were therefore assigned to
group S. Their profile at the time of initial treatment re-
sembled that of the 25 patientswhose neck lesionswere all
classified as indeterminate (43%) (group I). Group S pa-
tients had significantly larger primary tumors, their initial
treatment was more likely to include RRA, and they had
a higher rate of postoperative whole-body scan showing
neck uptake outside the thyroid bed. There were no sig-
nificant differences in American Joint Committee on Can-
cer (AJCC) stages or the initial ATA risk classification. At
study entry, however, the differences between the two
groups were more marked, involving disease stage, pres-
ence of distant metastases, and a history of revision sur-
gery (Table 2).
Table 1. Classification of Lesions Noted on Neck Ultrasound
ETA Classification (n  27) Thyroid Bed Lesions (n  24–26) Lymph Nodes (n  23)
Suspicious Increased vascularization Peripheral vascularization
Microcalcifications Microcalcifications
Cystic areas Cystic areas
Irregular borders Solid thyroid-like tissue
Taller than wide in transverse plane
Indeterminate Hypoechogenicity Round shape
Hilum absent
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Table 3 summarizes the characteristics of the 94 neck
lesions visualized by our staff at baseline, which included
16 thyroid bed masses and 78 lymph nodes. The 49 sus-
picious lesions (52%) were significantly larger than those
classified as indeterminate. Ten thyroid bed lesions (63%)
were hypoechoic nodules with no other abnormal fea-
tures.Almost all the78abnormal lymphnodeswere round
with no detectable hilum; 43 also presented one or more
suspicious features (the most common combination being
solid aspect with cystic areas and microcalcifications).
Table 2. Characteristics of the Study Cohort and Subcohorts
Characteristicsa Whole Cohort Group I Group S P Value
Patients, n 58 25 33
Females 36 (62%) 19 (76%) 17 (52%) .06
At initial treatment
Age, y, median (range) 46 (15–78) 46 (21–73) 45 (15–78) .41
Total thyroidectomy with neck dissection
With central neck dissection 13 (22%) 6 (24%) 7 (21%) .45
With lateral neck dissection 2 (3%) 2 (6%)
With central and lateral neck dissection 10 (17%) 2 (8%) 8 (24%)
Radioiodine remnant ablation 47 (81%) 16 (64%) 31 (94%) .004
RAI activity, mCi, median (range) 105 (30–300) 120 (42–300) 100 (30–155) .61
RxWBS (n  41)b
No uptake or uptake in thyroid bed 34 (83%) 15 (100%) 19 (73%) .03
Uptake outside the thyroid bedc 7 (17%) 7 (27%)
Histology subtype
PTC, classic 31 (54%) 13 (52%) 18 (55%) .60
PTC, follicular variant 20 (34%) 10 (40%) 10 (30%)
PTC, aggressive variantd 7 (12%) 2 (8%) 5 (15%)
Largest tumor diameter, mm 11 10 12 .02
Median (range) (n  53)b (1.1–45) (1.1–35) (4–45)
Tumor foci (n  57)b
Unifocal 32 (56%) 17 (68%) 15 (47%) .19
Multifocal 25 (44%) 8 (32%) 17 (53%)
Extrathyroidal extension 19 (33%) 4 (16%) 15 (45%)
Microscopic (T3) 18 (31%) 4 (16%) 14 (42%) .055
Macroscopic (T4) 1 (2%) 1 (3%)
AJCC stage
I 39 (67%) 19 (76%) 20 (61%) .09
II 2 (3%) 2 (6%)
III 8 (14%) 5 (20%) 3 (9%)
IV 9 (16%) 1 (4%) 8 (24%)
Distant metastases 4 (7%) 0 4 (12%) .14
ATA risk class
Low 17 (29%) 10 (40%) 7 (21%) .06
Intermediate 32 (55%) 14 (56%) 18 (55%)
High 9 (16%) 1 (4%) 8 (24%)
At study entry (baseline)
Age, y, median (range) 50.7 (16–82) 51.7 (22–77) 49 (16–82) .52
AJCC stage
I 37 (64%) 19 (76%) 18 (55%) .01
II 3 (5%) 3 (9%)
III 7 (12%) 5 (20%) 2 (6%)
IV 11 (19%) 1 (4%) 10 (30%)
Distant metastases 9 (16%) 0 9 (27%) .007
Previous revision neck surgery 10 (17%) 1 (4%) 9 (27%) .03
TSH, IU/L, median (range) 0.29 (0.01–18.7) 0.31 (0.02–6.5) 0.28 (0.02–18.7) .75
Serum Tg, ng/mL, median (range) 0.2 (0.002–195.9) 0.17 (0.002–1) 0.25 (0.01–195.9) .28
TgAb status (n  54)b
Negative 41 (76%) 21 (84%) 20 (69%) .08
Positive 13 (24%) 4 (16%) 9 (31%)
Years from initial surgery, median (range) 1.2 (0.1–26) 0.5 (0.1–16) 1.9 (0.1–26) .11
Abbreviations: NA, not available; RAI, radioactive iodine; RxWBS, posttreatment whole-body scan; TgAb, anti-Tg antibodies.
a Unless otherwise stated, results are expressed as numbers (percentages).
b Number of patients with available data.
c Cervical and in two cases at distant sites.
d Two oxyphilic in group I; two tall cell, one sclerosing, one trabecular, and one poorly differentiated in group S.
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Follow-up
Ten patients (17%) (7 from group S) developed one or
more new neck lesions after baseline. The 19 new lesions
were almost all lymph nodes (n  17: six in level IV, five
in level III, four in level VI, and one each in levels II and
VII), and 10 (53%) (all observed in group S patients) were
considered suspicious. The total number of lesions fol-
lowed up in the study was thus 113 (Figure 1). At first
appearance, greater than half the 95 lymph node lesions
were classified as suspicious, whereas most of the 18 thy-
roid bed lesions were considered indeterminate. Only two
thyroid bed lesions displayed growth during follow-up,
but all 18 were still visualized at the final visit (median
3.7 y after baseline US, range 0.2–10.5). Growth was
slightlymore common in lymphnode lesions, regardless of
whether they were indeterminate or suspicious. At the fi-
nal visit, however, 17 of the abnormal lymph nodes had
disappeared, including one indeterminate lesion that had
formerly displayed growth. Lesion resolution was signif-
icantly more common among indeterminate nodal lesions
(P  .001 vs those considered suspicious). The two sus-
picious nodes that disappeared had both been detected in
the same patient and were both characterized by unde-
tectable hila and peripheral vascularization.
Figure 2 shows patient-level outcomes recorded in
groups I and S. Growth of one or more lesions during
follow-up was significantly more common in group S
(36% vs 8%, P  .01). In both groups, however, most
patients experienced no structural progression, and none
developed complications related to lesion growth. The fi-
nal neck US findings were completely negative in nine of
the 25 patients in group I (36%). This finding was signif-
icantly less common in group S (5%, P .014 vs group I).
The median time to normalization (from baseline to first
negative US) in these cases was 2.9 years (0.9–4.0 y), and
the median duration of the postnormalization follow-up
was 0.5 years (range 0–4.1 y).
As shown in Table 4, in all of the patientswhose lesions
ultimately disappeared, the basal serum Tg levels mea-
sured at the time of the last US examination were unde-
tectable (ie,0.2 ng/mL) or indeterminate (ie,1 ng/mL
with no evidence of Tg antibodies or with declining Tg
antibodies). The nine patients with evidence of distant
metastases (all in group S)were the same oneswith distant
Table 3. Characteristics of the 94 Neck Lesions Present at Baseline
Characteristics Total Indeterminate Suspicious P Value
Number of lesions, % 94 (100%) 45 (48%) 49 (52%)
Largest diameter, mm, median (range) 9.1 (3.9–36.4) 8.2 (3.9–36.4) 9.8 (5.7–26) .01
Location relative to primary tumor
Ipsilateral 68 (72%) 30 (67%) 38 (78%) .23
Contralateral 26 (28%) 15 (33%) 11 (22%)
Location
Level II 16 (17%) 6 (13%) 10 (21%) .29
Level III 20 (21%) 9 (20%) 11 (22%)
Level IV 26 (28%) 12 (27%) 14 (29%)
Level V 3 (3%) 3 (6%)
Level VI 11 (12%) 6 (13%) 5 (10%)
Level VII 2 (2%) 2 (4%)
Thyroid bed 16 (17%) 10 (23%) 6 (12%)
Ultrasound features
Thyroid bed nodules .001
Hypoechogenicity 10 (11%) 10 (22%)
Irregular margins 2 (2%) 2 (4%)
Solid with microcalcifications and cystic areas 2 (2%) 2 (4%)
Increased vascularization 2 (2%) 2 (4%)
Lymph nodes
Round with absent hilum 35 (37%) 35 (78%)
Round, absent hilum, and the following
Cystic changes 6 (7%) 6 (13%)
Microcalcifications 6 (7%) 6 (13%)
Cystic changes and microcalcifications 2 (2%) 2 (4%)
Solid 3 (3%) 3 (6%)
Solid with microcalcifications 5 (5%) 5 (10%)
Solid with microcalcifications and cystic areas 10 (11%) 10 (20%)
Solid with microcalcifications and cystic areas
and peripheral vascularization
1 (1%) 1 (2%)
Solid with microcalcifications and peripheral
vascularization
5 (5%) 5 (10%)
Peripheral vascularization 3 (3%) 3 (6%)
Absent hilum and peripheral vascularization 2 (2%) 2 (4%)
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metastases at baseline. Based on the data shown in the
table, the clinical judgment of the medical staff, and the
preferences of the patients, 8 of the 32 group S patients
with persistent neck lesions were referred for treatment,
and five others (three from group S, two from group I)
underwent FNAB for cytological assessment. In all 13
cases, pathology findings confirmed the presence of re-
current neck disease.
Discussion
We retrospectively analyzed the sonographic features of
neck lesions detected in 58PTCpatients treatedwith near-
total thyroidectomy, with or without RRA, to determine
whether they could provide guidance for surveillance
management decisions in the absence of FNAB. Using the
ETA’s recently published classificationof cervicalUS find-
ings, we divided our patient cohort
into two subgroups: those with at
least one lesion classified as suspi-
cious (group S) and those whose ab-
normalities all fell within the inde-
terminate category (group I) (27).All
of the patients were managed with
active surveillance based mainly on
serial US studies and serum Tg
assays.
In the cohort as a whole, struc-
tural progression rates during fol-
low-up (median 3.7 y) were low:
fewer than 20% of the patients de-
veloped new neck lesions, only 24%
experienced lesion growth, and none
experienced lesion-related complica-
tions. Most important, at the final
follow-up visit, 17% of the patients
had no abnormalities whatsoever on
Figure 2. Patients in groups I and S with persistent lesions at the final follow-up visit. In the 10
patients whose neck US findings normalized (17% of the cohort), the median time from baseline
to the first negative US examination was 2.9 years (range 0.9–4,0 y), and follow-up after US
normalization ranged from 0 to 4.1 years (median 0.5 y).
Figure 1. Appearance, classification, and outcomes of the neck lesions followed up during the study period. Criteria for lesion classification as
suspicious or indeterminate are shown in Table 1. Like the lesions present at baseline, new lesions that developed during follow-up were
considered only when visualized on two or more consecutive ultrasound scans. Growth was defined as an increase in largest diameter of greater
than 3 mm compared with that at initial detection. LNL, lymph node lesions; TBL, thyroid bed lesions.
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the US examination. However, the two subgroups were
characterized by significantly different disease behaviors
and outcomes. In group I, lesion growth was observed in
only 8% of the patients, and in 36% all lesions resolved
spontaneously over time. Lesion growth and persistence
were both much more common when one or more of the
patient’s lesions presented suspicious features: in 36% of
the group S patients, at least one lesion increased in size
during follow-up, and in 97%, abnormalities were still
detectable at the final visit. These findings suggest that, in
the presence of sonographically detected neck lesions, the
fact that the abnormalities are all indeterminate rather
than frankly suspicious adds support to a decision to defer
FNAB and/or additional treatment.
This is important because abnormal neck US findings
are common during the follow-up of DTC patients, par-
ticularly those with PTCs. Our cohort was selected from
a background population of more than 600 consecutive
DTC patients followed up in our center since 2005 with
one or more neck US examinations per year. As shown in
Supplemental Figure 1, almost 20% of these individuals
had at least one scan showing abnormalities, but the per-
centage decreased by approximately half when we con-
sidered only those whose lesions were still present at the
next visit. Ninety-five percent of the lesions that disap-
peared between the first and second scans were cervical
lymph nodes, and 83% of these displayed only indeter-
minate features. The same pattern emerged in the study
cohort itself (Figure 1).Resolution appears to bemuch less
common among thyroid bed nodules, which often repre-
sent foci of postoperative fibrosis or suture granulomas
(15, 29, 30).
Disappearance of nodes with suspicious features has
been reported (16). In our cohort, only two suspicious
nodes, both documented in the same patient on two
consecutive scans, resolved completely. The lesions
were located ipsilaterally to the primary tumor (one in
level IV, the other in level VI), and both had presented
with absent hila and evidence of peripheral vascular-
ization. Although the latter feature is regarded as a sen-
sitive and also relatively specific predictor of malig-
nancy, it is also observed in up to 18% of reactive nodes
(23). Size increases are also compatible with reactive
phenomena, and this is a plausible explanation for the
single lesion in group I that disappeared after exhibiting
growth of 7 mm.
It is important to note that the US-based risk class de-
fined at the first sign of neck lesions may require periodic
revision owing to the appearance of new abnormalities
and/or changes in the appearance of those originally pres-
ent. Neither of these situations occurred within our study.
As for the 19 new lesions, only 10 were classified as sus-
picious, and all 10 developed in patients already assigned
to group S. Aside from size changes, the sonographic char-
acteristics of the baseline lesions in our cohort did not vary
appreciably during follow-up. As expected, the US-based
risk classification showed concordance with other clinical
predictorsof recurrent thyroid cancer. For example, group
S patients also tended to have higher-stage tumors and
were more likely to have undergone revision neck surgery
Table 4. Patient-Level Outcomes in Groups I and S at the Final Visit
Findings at Last Visita
Group I Group S
Patients With
Persistent Lesions
(n  16)
Patients With
No Lesions
(n  9)
Patients With
No Lesions
(n  1)
Patients With
Persistent Lesions
(n  32)
Basal serum Tgb
Undetectable levels 7 (44%) 6 (67%) 10 (31%)
Detectable levels 7 (44%) 2 (22%)c 20 (63%)
Uninterpretable 2 (12%) 1 (11%)d 1 (100%)d 2 (6%)
Serum TSH, IU/L, median
(range)
0.5 (0.09–12.6) 0.22 (0.06–1.4) 5.3 0.31 (0–3.2)
Presence of distant
metastases
9 (28%)
Follow-up, y, median (range)
(baseline US to last US)
2.8 (0.2–7.7) 1.6 (0.2–3) 2.1 2.5 (0.2–10.5)
Abbreviation: TgAb, anti-Tg antibodies.
a Expressed as number (percentage) of patients unless otherwise stated.
b Basal Tg levels were classified as follows: undetectable, less than 0.2 ng/mL and negative TgAb status; detectable, greater than 0.2 ng/mL and
negative TgAb status; and uninterpretable, any Tg level and positive or unknown TgAb status.
c Tg levels less than 1 ng/mL.
d Declining TgAb levels.
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for persistent/recurrent PTCprior to study entry (Table 2);
they also had higher Tg levels at the final assessment.
Previous studies (15, 16) have already shown that neck
lesions detected sonographically during the postoperative
follow-up of DTC patients frequently follow an indolent
course and that noninvasive surveillance is usually a safe,
cost-effective strategy formanaging cases of this type. The
outcomes observed in our study suggest that postponing
invasive procedures such as FNA or further treatments is
a safe course of action, even in populationwith higher-risk
profiles, particularly when the neck lesions are character-
ized by exclusively indeterminate features.
The main limits of this study were the retrospective
nature of our analyses and the small size of the study co-
hort. It is also important to stress that the present study
was conducted in a single center, and all the US examina-
tions were performed by a single physician with extensive
training and experience. These factors may well have en-
hanced the uniformity of the examinations themselves and
the descriptions of findings. However, they might also
reduce the applicability of our study findings to other set-
tings. The main shortcoming of cervical US is its operator
dependence. The impact of this problem canbe attenuated
to some extent by theuse of standardized examination and
reporting protocols, such as those proposed by the ETA
(27). Greater uniformity would not only improve com-
munication between clinicians, but also it would also fa-
cilitate comparison of the findings from different studies,
an essential step for identifyinghigh-quality, cost-effective
management strategies (31).
In conclusion, previous studies (15, 16) have shown
that neck lesions detected sonographically during the
postoperative follow-up of DTC patients frequently fol-
low an indolent course and that noninvasive surveillance
is usually a safe, cost-effective strategy formanaging cases
of this type. Our study expands these findings. The out-
comes we observed suggest that watchful waiting can be a
safe course of action, even in population with higher-risk
profiles, particularly when the neck lesions are character-
ized by exclusively indeterminate sonographic features.
Risk estimates based on the ETA’s evidence-based classi-
fication of sonographically detected neck abnormalities
can be a useful aid for identifying PTC patients for whom
a more relaxed follow-up protocol can be proposed. In-
vasive procedures and additional imaging studies can then
be reserved for cases in which the neck lesions are most
likely to pose an actual threat.
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